BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 20839949)

  • 1. A phase I study of docetaxel, oxaliplatin, & capecitabine (DOC) as first-line therapy of patients with locally advanced or metastatic adenocarcinoma of stomach and GE junction.
    Malik I; Bernal P; Byrd J
    Cancer Invest; 2010 Oct; 28(8):833-8. PubMed ID: 20839949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer.
    Andersen M; Schønnemann KR; Yilmaz M; Jensen HA; Vestermark LW; Pfeiffer P
    Acta Oncol; 2010 Nov; 49(8):1246-52. PubMed ID: 20429725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas.
    Lo SS; Khorana AA; Javle M; Simon S; Kiefer G; Rajasenan K; Wang H; Hantel A; Shayne M; Hwang J; Schmotzer A; Ramanathan RK
    Oncology; 2010; 78(2):125-9. PubMed ID: 20389134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
    Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer.
    Evans D; Miner T; Akerman P; Millis R; Jean M; Kennedy T; Safran H
    Am J Clin Oncol; 2007 Aug; 30(4):346-9. PubMed ID: 17762433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
    J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study.
    van Meerten E; Eskens FA; van Gameren EC; Doorn L; van der Gaast A
    Br J Cancer; 2007 May; 96(9):1348-52. PubMed ID: 17437008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New recommendation of doses in an ongoing phase II study of docetaxel, oxaliplatin and capecitabine as first line therapy in advanced gastro-oesophageal cancer.
    Schønnemann KR; Yilmaz M; Andersen M; Pfeiffer P
    Acta Oncol; 2011 Jan; 50(1):151-2. PubMed ID: 20843172
    [No Abstract]   [Full Text] [Related]  

  • 9. Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer.
    Liu C; Sun Q; Hang X; Zhong B; Wang D
    Anticancer Drugs; 2008 Sep; 19(8):825-31. PubMed ID: 18690095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.
    Goel G; Jauhri M; Negi A; Aggarwal S
    Hematol Oncol Stem Cell Ther; 2010; 3(2):55-9. PubMed ID: 20543537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of oxaliplatin in combination with capecitabine and radiotherapy as postoperative treatment for stage II and III rectal cancer.
    Jin J; Li YX; Wang JW; Wang WH; Liu YP; Wang K; Fang H; Zhou ZX; Zhou AP; Yu ZH
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):671-7. PubMed ID: 18455328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer.
    Amarantidis K; Xenidis N; Chelis L; Chamalidou E; Dimopoulos P; Michailidis P; Tentes A; Deftereos S; Karanikas M; Karayiannakis A; Kakolyris S
    Oncology; 2011; 80(5-6):359-65. PubMed ID: 21811088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxaliplatin and capecitabine-based chemoradiotherapy for gastric cancer--an extended phase I MARGIT and AIO trial.
    Hofheinz RD; Wenz F; Lukan N; Mai S; Kripp M; Staiger W; Schwarzbach M; Willeke F; Möhler M; Post S; Hochhaus A
    Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):142-7. PubMed ID: 18539404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study.
    Stein A; Arnold D; Thuss-Patience PC; Moehler M; Grothe W; Seufferlein T; Reinacher-Schick A; Geissler M; Hofheinz RD; Schmoll HJ
    Acta Oncol; 2014 Mar; 53(3):392-8. PubMed ID: 24024696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.
    Di Lauro L; Vici P; Belli F; Tomao S; Fattoruso SI; Arena MG; Pizzuti L; Giannarelli D; Paoletti G; Barba M; Sergi D; Maugeri-Saccà M
    Gastric Cancer; 2014 Oct; 17(4):718-24. PubMed ID: 24318671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer.
    Dupont J; Jensen HA; Jensen BV; Pfeiffer P
    Acta Oncol; 2007; 46(3):330-5. PubMed ID: 17450468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma.
    Fakih MG; Bullarddunn K; Yang GY; Pendyala L; Toth K; Andrews C; Rustum YM; Ross ME; Levea C; Puthillath A; Park YM; Rajput A
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):650-7. PubMed ID: 18565686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer: a phase II study.
    Evans D; Miner T; Iannitti D; Akerman P; Cruff D; Maia-Acuna C; Harrington D; Habr F; Chauhan B; Berkenblit A; Stuart K; Sears D; Kennedy T; Safran H
    Cancer Invest; 2007 Sep; 25(6):445-8. PubMed ID: 17882656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.
    Kakolyris S; Souglakos J; Kouroussis C; Androulakis N; Samonis G; Vardakis N; Amarantidis K; Agelaki S; Mavroudis D; Xenidis N; Georgoulias V
    Oncology; 2004; 66(4):253-9. PubMed ID: 15218291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patients.
    Frustaci S; Buonadonna A; Turchet E; Corona G; Tabaro G; Miolo G; Torrisi E; Lo Re G; Tumolo S; Toffoli G
    Int J Clin Oncol; 2013 Jun; 18(3):510-6. PubMed ID: 22669361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.